Eversept Partners LP Sells 1,131,005 Shares of Evolus, Inc. $EOLS

Eversept Partners LP trimmed its position in shares of Evolus, Inc. (NASDAQ:EOLS) by 76.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 344,104 shares of the company’s stock after selling 1,131,005 shares during the quarter. Eversept Partners LP owned approximately 0.53% of Evolus worth $2,288,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in EOLS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Evolus by 5.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,289 shares of the company’s stock worth $400,000 after buying an additional 1,838 shares during the last quarter. Millennium Management LLC increased its stake in shares of Evolus by 1.7% in the first quarter. Millennium Management LLC now owns 1,392,028 shares of the company’s stock valued at $16,746,000 after buying an additional 23,605 shares in the last quarter. Jones Financial Companies Lllp acquired a new stake in shares of Evolus in the first quarter valued at $158,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Evolus by 36.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,565 shares of the company’s stock valued at $1,883,000 after buying an additional 41,513 shares in the last quarter. Finally, Jane Street Group LLC increased its stake in shares of Evolus by 484.8% in the first quarter. Jane Street Group LLC now owns 69,947 shares of the company’s stock valued at $841,000 after buying an additional 57,987 shares in the last quarter. 90.69% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, insider David Moatazedi sold 13,669 shares of the stock in a transaction that occurred on Friday, March 20th. The shares were sold at an average price of $4.75, for a total value of $64,927.75. Following the transaction, the insider directly owned 604,700 shares in the company, valued at $2,872,325. This represents a 2.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 5.00% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on EOLS shares. Wall Street Zen lowered shares of Evolus from a “buy” rating to a “hold” rating in a research report on Sunday, March 15th. Weiss Ratings upgraded shares of Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday. Finally, BTIG Research reiterated a “buy” rating and set a $13.00 target price on shares of Evolus in a research report on Wednesday. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Evolus Price Performance

Shares of NASDAQ EOLS opened at $6.74 on Thursday. The company’s 50 day simple moving average is $5.87 and its 200 day simple moving average is $5.55. Evolus, Inc. has a fifty-two week low of $3.86 and a fifty-two week high of $10.20. The firm has a market capitalization of $443.90 million, a P/E ratio of -10.06 and a beta of 1.34.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings data on Monday, May 4th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The company had revenue of $73.14 million for the quarter, compared to analyst estimates of $72.52 million. During the same quarter in the prior year, the company earned ($0.30) EPS. Sell-side analysts expect that Evolus, Inc. will post -0.38 EPS for the current fiscal year.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.